 | • レポートコード：MRC2Q12-19113 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンのグローバル市場のxxx％を占める「TJM-F92ストレイン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「農場」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンのグローバル主要プレイヤーには、Yongshun Creatures、Pfizer、Boehringer Ingelheim、Bayer、Elanco、MSD、Cahic、Ringpu、Baoling、Jizhong、Dahuanong、Hayao、Pulike Biology、Tecon、Sinovetなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場は、種類と用途によって区分されます。世界の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 TJM-F92ストレイン、GDr180ストレイン、JXA1-Rストレイン、その他 【用途別セグメント】 農場、個人 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン製品概要 - 種類別市場（TJM-F92ストレイン、GDr180ストレイン、JXA1-Rストレイン、その他） - 用途別市場（農場、個人） - 調査の目的 ・エグゼクティブサマリー - 世界の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン販売量予測2017-2028 - 世界の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン売上予測2017-2028 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの地域別販売量 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン販売量 - 主要メーカー別高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン売上 - 主要メーカー別高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（TJM-F92ストレイン、GDr180ストレイン、JXA1-Rストレイン、その他） - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの種類別販売量 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの種類別売上 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの種類別価格 ・用途別市場規模（農場、個人） - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの用途別販売量 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの用途別売上 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの用途別価格 ・北米市場 - 北米の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（種類別、用途別） - 主要国別の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（種類別、用途別） - 主要国別の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（種類別、用途別） - 主要国別の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（種類別、用途別） - 主要国別の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（種類別、用途別） - 主要国別の高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Yongshun Creatures、Pfizer、Boehringer Ingelheim、Bayer、Elanco、MSD、Cahic、Ringpu、Baoling、Jizhong、Dahuanong、Hayao、Pulike Biology、Tecon、Sinovet ・産業チェーン及び販売チャネル分析 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの産業チェーン分析 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの原材料 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの生産プロセス - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの販売及びマーケティング - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの産業動向 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンのマーケットドライバー - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの課題 - 高病原性ブタ生殖＆呼吸器症候群ワクチン＆生ワクチンの阻害要因 ・主な調査結果 |
Biologics for the prevention of reproductive and respiratory syndrome in pigs
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live include Yongshun Creatures, Pfizer, Boehringer Ingelheim, Bayer, Elanco, MSD, Cahic, Ringpu and Baoling, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market. Further, it explains the major drivers and regional dynamics of the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Yongshun Creatures
Pfizer
Boehringer Ingelheim
Bayer
Elanco
MSD
Cahic
Ringpu
Baoling
Jizhong
Dahuanong
Hayao
Pulike Biology
Tecon
Sinovet
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by kinds and by downstream segments based on sales, price, and value for the period 2017-2028.
Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Kinds
TJM-F92 Strain
GDr180 Strain
JXA1-R Strain
Other
Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Downstream
Farms
Individual
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Yongshun Creatures, Pfizer, Boehringer Ingelheim, Bayer, Elanco, MSD, Cahic, Ringpu and Baoling, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by kinds, by downstream and by country, sales and revenue for each segment.
Chapter 7: Europe by kinds, by downstream and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by kinds, by downstream and by country, sales and revenue for each segment.
Chapter 9: Latin America by kinds, by downstream and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by kinds, by downstream and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Introduction
1.2 Market by Kinds
1.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Kinds, 2017 VS 2021 VS 2028
1.2.2 TJM-F92 Strain
1.2.3 GDr180 Strain
1.2.4 JXA1-R Strain
1.2.5 Other
1.3 Market by Downstream
1.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Downstream, 2017 VS 2021 VS 2028
1.3.2 Farms
1.3.3 Individual
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Estimates and Forecasts 2017-2028
2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Estimates and Forecasts 2017-2028
2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region
2.4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2017-2022)
2.4.2 Global Sales Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Region (2023-2028)
2.5 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region
2.5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2017-2022)
2.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Manufacturers
3.1.1 Global Top Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturers by Sales (2017-2022)
3.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live in 2021
3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Manufacturers
3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Manufacturers (2017-2022)
3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue in 2021
3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Kinds
4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds
4.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Sales by Kinds (2017-2022)
4.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Sales by Kinds (2023-2028)
4.1.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2028)
4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds
4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Revenue by Kinds (2017-2022)
4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Revenue by Kinds (2023-2028)
4.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Kinds (2017-2028)
4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Kinds
4.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Kinds (2017-2022)
4.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Kinds (2023-2028)
5 Market Size by Downstream
5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream
5.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Sales by Downstream (2017-2022)
5.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Sales by Downstream (2023-2028)
5.1.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2028)
5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream
5.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Revenue by Downstream (2017-2022)
5.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Revenue by Downstream (2023-2028)
5.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Downstream (2017-2028)
5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Downstream
5.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Downstream (2017-2022)
5.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Downstream (2023-2028)
6 North America
6.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Kinds
6.1.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2028)
6.1.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2028)
6.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Downstream
6.2.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2028)
6.2.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2028)
6.3 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country
6.3.1 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2028)
6.3.2 North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Kinds
7.1.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2028)
7.1.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2028)
7.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Downstream
7.2.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2028)
7.2.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2028)
7.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country
7.3.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2028)
7.3.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Kinds
8.1.1 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2028)
8.1.2 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2028)
8.2 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Downstream
8.2.1 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2028)
8.2.2 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2028)
8.3 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Region
8.3.1 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2017-2028)
8.3.2 Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Kinds
9.1.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2028)
9.1.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2028)
9.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Downstream
9.2.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2028)
9.2.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2028)
9.3 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country
9.3.1 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2028)
9.3.2 Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Kinds
10.1.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2028)
10.1.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2028)
10.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Downstream
10.2.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2028)
10.2.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2028)
10.3 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country
10.3.1 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2028)
10.3.2 Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Yongshun Creatures
11.1.1 Yongshun Creatures Corporation Information
11.1.2 Yongshun Creatures Overview
11.1.3 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Yongshun Creatures Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Overview
11.3.3 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Boehringer Ingelheim Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Overview
11.4.3 Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bayer Recent Developments
11.5 Elanco
11.5.1 Elanco Corporation Information
11.5.2 Elanco Overview
11.5.3 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Elanco Recent Developments
11.6 MSD
11.6.1 MSD Corporation Information
11.6.2 MSD Overview
11.6.3 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 MSD Recent Developments
11.7 Cahic
11.7.1 Cahic Corporation Information
11.7.2 Cahic Overview
11.7.3 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Cahic Recent Developments
11.8 Ringpu
11.8.1 Ringpu Corporation Information
11.8.2 Ringpu Overview
11.8.3 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Ringpu Recent Developments
11.9 Baoling
11.9.1 Baoling Corporation Information
11.9.2 Baoling Overview
11.9.3 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Baoling Recent Developments
11.10 Jizhong
11.10.1 Jizhong Corporation Information
11.10.2 Jizhong Overview
11.10.3 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Jizhong Recent Developments
11.11 Dahuanong
11.11.1 Dahuanong Corporation Information
11.11.2 Dahuanong Overview
11.11.3 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Dahuanong Recent Developments
11.12 Hayao
11.12.1 Hayao Corporation Information
11.12.2 Hayao Overview
11.12.3 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Hayao Recent Developments
11.13 Pulike Biology
11.13.1 Pulike Biology Corporation Information
11.13.2 Pulike Biology Overview
11.13.3 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Pulike Biology Recent Developments
11.14 Tecon
11.14.1 Tecon Corporation Information
11.14.2 Tecon Overview
11.14.3 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Tecon Recent Developments
11.15 Sinovet
11.15.1 Sinovet Corporation Information
11.15.2 Sinovet Overview
11.15.3 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Sinovet Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Chain Analysis
12.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Production Mode & Process
12.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales and Marketing
12.4.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Channels
12.4.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors
12.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Trends
13.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
13.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
13.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
14 Key Findings in The Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Kinds, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of TJM-F92 Strain
Table 3. Major Manufacturers of GDr180 Strain
Table 4. Major Manufacturers of JXA1-R Strain
Table 5. Major Manufacturers of Other
Table 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Downstream, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2017-2022) & (Box)
Table 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2017-2022)
Table 10. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2023-2028) & (Box)
Table 11. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2023-2028)
Table 12. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2017-2022)
Table 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2023-2028)
Table 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Manufacturers (2017-2022) & (Box)
Table 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Manufacturers (2017-2022)
Table 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Manufacturers (2017-2022)
Table 20. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Manufacturers (2017-2022) &(US$/Box)
Table 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live as of 2021)
Table 23. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Offered
Table 25. Date of Manufacturers Enter into Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 28. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2023-2028) & (Box)
Table 29. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Kinds (2017-2022)
Table 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Kinds (2023-2028)
Table 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2022) & (US$ Million)
Table 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2023-2028) & (US$ Million)
Table 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Kinds (2017-2022)
Table 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Kinds (2023-2028)
Table 35. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Kinds (2017-2022) & (US$/Box)
Table 36. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Kinds (2023-2028) & (US$/Box)
Table 37. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 38. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2023-2028) & (Box)
Table 39. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Downstream (2017-2022)
Table 40. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Downstream (2023-2028)
Table 41. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2022) & (US$ Million)
Table 42. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2023-2028) & (US$ Million)
Table 43. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Downstream (2017-2022)
Table 44. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Downstream (2023-2028)
Table 45. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Downstream (2017-2022) & (US$/Box)
Table 46. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Downstream (2023-2028) & (US$/Box)
Table 47. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 48. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2023-2028) & (Box)
Table 49. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2022) & (US$ Million)
Table 50. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2023-2028) & (US$ Million)
Table 51. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 52. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2023-2028) & (Box)
Table 53. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2022) & (US$ Million)
Table 54. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2023-2028) & (US$ Million)
Table 55. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022) & (Box)
Table 56. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2023-2028) & (Box)
Table 57. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 60. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2023-2028) & (Box)
Table 61. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2022) & (US$ Million)
Table 62. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2023-2028) & (US$ Million)
Table 63. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 64. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2023-2028) & (Box)
Table 65. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2022) & (US$ Million)
Table 66. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2023-2028) & (US$ Million)
Table 67. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022) & (Box)
Table 68. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2023-2028) & (Box)
Table 69. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 72. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2023-2028) & (Box)
Table 73. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2022) & (US$ Million)
Table 74. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2023-2028) & (US$ Million)
Table 75. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 76. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2023-2028) & (Box)
Table 77. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2022) & (US$ Million)
Table 78. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2023-2028) & (US$ Million)
Table 79. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2017-2022) & (Box)
Table 80. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2023-2028) & (Box)
Table 81. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 84. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2023-2028) & (Box)
Table 85. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2022) & (US$ Million)
Table 86. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2023-2028) & (US$ Million)
Table 87. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 88. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2023-2028) & (Box)
Table 89. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2022) & (US$ Million)
Table 90. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2023-2028) & (US$ Million)
Table 91. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022) & (Box)
Table 92. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2023-2028) & (Box)
Table 93. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2017-2022) & (Box)
Table 96. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Kinds (2023-2028) & (Box)
Table 97. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Kinds (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2017-2022) & (Box)
Table 100. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Downstream (2023-2028) & (Box)
Table 101. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Downstream (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2017-2022) & (Box)
Table 104. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2023-2028) & (Box)
Table 105. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2023-2028) & (US$ Million)
Table 107. Yongshun Creatures Corporation Information
Table 108. Yongshun Creatures Description and Major Businesses
Table 109. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 110. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Yongshun Creatures Recent Developments
Table 112. Pfizer Corporation Information
Table 113. Pfizer Description and Major Businesses
Table 114. Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 115. Pfizer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Pfizer Recent Developments
Table 117. Boehringer Ingelheim Corporation Information
Table 118. Boehringer Ingelheim Description and Major Businesses
Table 119. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 120. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Boehringer Ingelheim Recent Developments
Table 122. Bayer Corporation Information
Table 123. Bayer Description and Major Businesses
Table 124. Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 125. Bayer Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Bayer Recent Developments
Table 127. Elanco Corporation Information
Table 128. Elanco Description and Major Businesses
Table 129. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 130. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Elanco Recent Developments
Table 132. MSD Corporation Information
Table 133. MSD Description and Major Businesses
Table 134. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 135. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. MSD Recent Developments
Table 137. Cahic Corporation Information
Table 138. Cahic Description and Major Businesses
Table 139. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 140. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Cahic Recent Developments
Table 142. Ringpu Corporation Information
Table 143. Ringpu Description and Major Businesses
Table 144. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 145. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Ringpu Recent Developments
Table 147. Baoling Corporation Information
Table 148. Baoling Description and Major Businesses
Table 149. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 150. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Baoling Recent Developments
Table 152. Jizhong Corporation Information
Table 153. Jizhong Description and Major Businesses
Table 154. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 155. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Jizhong Recent Developments
Table 157. Dahuanong Corporation Information
Table 158. Dahuanong Description and Major Businesses
Table 159. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 160. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Dahuanong Recent Developments
Table 162. Hayao Corporation Information
Table 163. Hayao Description and Major Businesses
Table 164. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 165. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Hayao Recent Developments
Table 167. Pulike Biology Corporation Information
Table 168. Pulike Biology Description and Major Businesses
Table 169. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 170. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Pulike Biology Recent Developments
Table 172. Tecon Corporation Information
Table 173. Tecon Description and Major Businesses
Table 174. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 175. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Tecon Recent Developments
Table 177. Sinovet Corporation Information
Table 178. Sinovet Description and Major Businesses
Table 179. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 180. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Sinovet Recent Developments
Table 182. Key Raw Materials Lists
Table 183. Raw Materials Key Suppliers Lists
Table 184. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors List
Table 185. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customers List
Table 186. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Trends
Table 187. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
Table 188. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
Table 189. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources
List of Figures
Figure 1. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Picture
Figure 2. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Kinds in 2021 & 2028
Figure 3. TJM-F92 Strain Product Picture
Figure 4. GDr180 Strain Product Picture
Figure 5. JXA1-R Strain Product Picture
Figure 6. Other Product Picture
Figure 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Downstream in 2021 & 2028
Figure 8. Farms
Figure 9. Individual
Figure 10. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Report Years Considered
Figure 11. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales 2017-2028 (Box)
Figure 12. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue 2017-2028 (US$ Million)
Figure 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2017-2022)
Figure 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2023-2028)
Figure 17. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2017-2028) & (Box)
Figure 18. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2017-2028) & (Box)
Figure 20. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2017-2028) & (Box)
Figure 22. Asia-Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2017-2028) & (Box)
Figure 24. Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2017-2028) & (Box)
Figure 26. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live in the World: Market Share by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue in 2021
Figure 29. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2028)
Figure 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Kinds (2017-2028)
Figure 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2028)
Figure 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Downstream (2017-2028)
Figure 34. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2028)
Figure 35. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Kinds (2017-2028)
Figure 36. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2028)
Figure 37. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Downstream (2017-2028)
Figure 38. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Country (2017-2028)
Figure 39. North America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Country (2017-2028)
Figure 40. United States Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2028)
Figure 43. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Kinds (2017-2028)
Figure 44. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2028)
Figure 45. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Downstream (2017-2028)
Figure 46. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Country (2017-2028)
Figure 47. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Country (2017-2028)
Figure 48. Germany Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2017-2028) & (US$ Million)
Figure 49. France Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Kinds (2017-2028)
Figure 54. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Kinds (2017-2028)
Figure 55. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Downstream (2017-2028)
Figure 56. Asia Pacific Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Downstream (2017-2028)
Figure 57. Asia Pacific Highly Patho